Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A SPECT-Guided, PET-Sparing Algorithm for PSMA Radiopharmaceutical Therapy Evaluation (SPARE).

Created on 13 Nov 2026

Authors

Mutaz Kassas, Mourad Zekri, Raluca Poenaru, Paulus Kristanto, Ioannis Karfis, Patrick Flamen, Carlos Artigas

Published in

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Nov 12, 2026. Epub Nov 12, 2026.

Abstract

[177Lu]Lu-PSMA radiopharmaceutical therapy is delivered as repeated cycles, yet the decision to continue or adapt treatment after the second cycle is not standardized. Posttherapy SPECT/CT is routinely performed but rarely used formally for response assessment. We developed a multimodality, response-adapted algorithm applied after cycle 2 and tested its concordance with real-world decisions. Methods: We studied 142 men with metastatic androgen pathway modulator-resistant prostate cancer (formerly metastatic castration-resistant prostate cancer) who completed at least 2 cycles of [177Lu]Lu-PSMA and underwent posttherapy SPECT/CT, baseline and 12-wk prostate-specific antigen (PSA) testing, and baseline and interim prostate-specific membrane antigen (PSMA) PET and [18F]FDG PET. Response was assessed in accordance with Prostate Cancer Working Group 4 recommendations for PSA and with RECIP 1.0 for SPECT and PSMA PET. The algorithm combined SPECT/CT and PSA, used PSMA PET only when both were stable, and yielded 3 recommendations: continue [177Lu]Lu-PSMA, discontinue [177Lu]Lu-PSMA, or consider [18F]FDG PET. The primary endpoints were the number of interim PSMA PET studies avoided and the concordance between algorithm recommendations (continue vs. discontinue) and real-world decisions. The secondary endpoint was intermodality response evaluation concordance. Results: The algorithm recommended continuation in 74 patients (52.1%), discontinuation in 49 patients (34.5%), and [18F]FDG PET in 19 patients (13.4%). Interim PSMA PET/CT could be avoided in 120 patients (84.5%) (95% CI, 77.7%-89.5%). Among patients with a definitive recommendation, conditional agreement of the algorithm with real-world management decisions was 91.1% (95% CI, 84.7%-94.9%), with a κ of 0.81 (95% CI, 0.69-0.91). All 74 patients (100%) with an algorithm recommendation to continue treatment had matching real-world decisions for treatment continuation, whereas 38 (78%) of 49 patients with an algorithm recommendation to discontinue treatment had matching real-world decisions for treatment discontinuation. Response classification on SPECT agreed only moderately with PSA level (κ = 0.45) and PSMA PET (κ = 0.47), but the combination of SPECT and PSA raised agreement with PSMA PET to "substantial" (κ = 0.67), approaching that of PSMA PET with PSA level (κ = 0.70). Every discordant decision (n = 11) occurred when the algorithm recommended treatment discontinuation in a patient who nonetheless continued treatment, most commonly because [177Lu]Lu-PSMA was being used as a last line of therapy (7/11, 64%). Conclusion: A SPECT-guided algorithm could have avoided most interim PSMA PET studies and reproduced real-world treatment decisions after 2 cycles of [177Lu]Lu-PSMA with high agreement. This algorithm may serve as the basis for a standardized treatment management framework, pending independent, prospective outcome-based validation.

PMID:
43020617
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 67
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement